DocGo (DCGO) Q2 2026 earnings review
Core Growth Excites, But a Slashed Profit Target Exposes Severe Cash Pressures
DocGo is successfully executing its operational pivot from temporary migrant contracts to a recurring digital health model, but the financial toll is accelerating. While core (ex-migrant) revenue grew 19% YoY in Q2, management abruptly reversed its profitability outlook, slashing full-year Adjusted EBITDA guidance to a $17M-$22M loss. Dwindling unrestricted cash ($25.2M) forced a creative lifeline: acquiring virtual care provider Hicuity Health largely by assuming $52M in debt from Perceptive Advisors, who provided an additional $50M credit facility. The top-line transformation is working, but the cash burn is a blaring siren.
🐂 Bull Case
Migrant revenue hit $0 in Q2, fully completing the wind-down. Excluding these programs, total revenue grew a healthy 19% YoY, proving the underlying digital health and transport businesses are scaling.
Buying Hicuity Health adds $65M in LTM revenue, $4.5M in EBITDA, and crucial Tele-ICU capabilities. Crucially, the deal brings a new $50M debt facility from Perceptive Advisors, alleviating near-term liquidity fears.
🐻 Bear Case
Despite stripping $4M in SG&A, management widened the FY26 Adjusted EBITDA loss guidance from $5-$10M to $17-$22M, suggesting deep operational inefficiencies in the rapidly growing virtual care segments.
Total cash plummeted from $128.7M a year ago to just $48.1M today (with only $25.2M unrestricted). The company had to finance the Hicuity deal via debt assumption and equity dilution because it lacked cash.
⚖️ Verdict: 🔴
Bearish. The strategic expansion into high-acuity virtual care is promising, but expanding EBITDA losses and a precarious cash position severely limit execution flexibility. The company bought itself a lifeline with Perceptive's debt, but margin stabilization is completely unproven.
Key Themes
EBITDA Outlook Reversing Sharply
After confidently projecting an Adjusted EBITDA loss of just $5M-$10M in Q1, management abruptly revised this to a $17M-$22M loss for FY26. This massive deceleration contradicts the narrative of operational leverage and suggests the rapid growth in areas like SteadyMD is coming at a steep cost—likely driven by previously noted labor inefficiencies, hiring incentives, and unhedged fuel costs.
Hicuity Health Acquisition Transforms Footprint
The pending acquisition of Hicuity Health pushes DocGo deeper into high-acuity virtual care (Tele-ICU, Virtual Nursing, Telemetry). With $65M in LTM revenue and $4.5M in EBITDA, it immediately adds scale. Structured creatively, DocGo acquires it by assuming ~$52M in debt to Perceptive Advisors, preserving its fragile cash balance while bridging hospital-to-home care continuums.
Unrestricted Cash Base Hits Critical Low
Working capital pressures are accelerating. Total cash and equivalents (including restricted) fell to $48.1M from $59.9M last quarter. More alarming, unrestricted cash sits at just $25.2M. The company relies heavily on the collection of overdue NYC migrant receivables, and without the newly secured Perceptive Advisors debt facility, the balance sheet would be highly stressed.
Core Mobile Health Volumes Surging
Excluding the defunct migrant programs, the Mobile Health segment is an accelerating growth engine. Revenue hit $21.4M (up 78% YoY organically and via SteadyMD). Record volumes were reported across the board: Virtual Care & Lab orders (+58%), Healthcare in the Home (+26%), and Mobile Phlebotomy (+20%).
Payer Relationships Deepening
The patient base assigned for care gap closure services reached 1.7 million, up 100,000 from Q1. A new contract with a major national health plan in Pennsylvania further validates the population health model, proving that payers see value in DocGo's ability to locate and treat unattached members.
Other KPIs
Stable. Up 5% from $49.6 million in the prior year quarter. Volumes increased 15%, but revenue growth slightly lagged volume, pointing to potential mix shifts or pricing pressures. Adjusted gross margin for the segment remained robust at 32.0%.
Decelerating. Down from 31.6% a year ago. Despite eliminating the low-margin migrant revenue, consolidated margins shrunk, likely hindered by clinical labor costs in the virtual care division and sustained elevated fuel costs for the transport fleet.
The company successfully removed over $4 million in estimated annual SG&A costs during the quarter. However, the severe worsening of EBITDA guidance implies these savings were entirely consumed by gross margin pressures or other unforeseen operational costs.
Guidance
Stable. The range was narrowed slightly from the previous $300-$315 million. This excludes any contribution from the pending Hicuity Health acquisition. Compared to FY25's $322M (which included heavy migrant revenue), this implies a total YoY contraction, but high double-digit growth for the core base business.
Reversing sharply from prior guidance of $(5) - $(10) million. Management still claims they will 'exit the year at a profitable run rate', but this updated guidance requires taking a significantly deeper loss in Q3 before seeing any potential fourth-quarter turnaround.
Key Questions
Bridge to Profitability
You widened the FY26 EBITDA loss guidance by roughly $12 million at the midpoint despite removing $4 million in SG&A. What specific expense lines blew out in Q2 to force this revision?
Hicuity Debt Structure
The $52 million of Perceptive debt assumed in the Hicuity acquisition matures in late 2029. What are the cash interest obligations and financial covenants attached to this facility given the current unrestricted cash balance of $25M?
NYC Migrant Receivables
Working capital continues to drain. Has the city audit concluded, and what is the exact timeline for collecting the remaining $13+ million in receivables from the NYC HPD?
Hicuity Margin Profile
Hicuity brings $65M in revenue and $4.5M in EBITDA (~7% margin). Does this structurally dilute the long-term margin profile of the Mobile Health segment, or are there immediate synergies to expand that margin?